ATE333287T1 - Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten - Google Patents

Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten

Info

Publication number
ATE333287T1
ATE333287T1 AT99922536T AT99922536T ATE333287T1 AT E333287 T1 ATE333287 T1 AT E333287T1 AT 99922536 T AT99922536 T AT 99922536T AT 99922536 T AT99922536 T AT 99922536T AT E333287 T1 ATE333287 T1 AT E333287T1
Authority
AT
Austria
Prior art keywords
prophylaxis
treatment
demyelinating diseases
autoimmune demyelinating
fas
Prior art date
Application number
AT99922536T
Other languages
English (en)
Inventor
Takehiro Yatomi
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE333287T1 publication Critical patent/ATE333287T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99922536T 1998-05-29 1999-05-28 Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten ATE333287T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14953098 1998-05-29

Publications (1)

Publication Number Publication Date
ATE333287T1 true ATE333287T1 (de) 2006-08-15

Family

ID=15477161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922536T ATE333287T1 (de) 1998-05-29 1999-05-28 Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten

Country Status (6)

Country Link
US (1) US6759041B1 (de)
EP (1) EP1082967B1 (de)
AT (1) ATE333287T1 (de)
CA (1) CA2333880A1 (de)
DE (1) DE69932434D1 (de)
WO (1) WO1999062554A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19959049A1 (de) * 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
US7848848B2 (en) * 2006-04-28 2010-12-07 Freeslate, Inc. Robotic station for capturing both image and weight of a sample
US7875589B2 (en) 2006-12-11 2011-01-25 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for rheumatoid arthritis
US8771689B2 (en) 2006-12-11 2014-07-08 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for ischemia or inflammation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63230629A (ja) * 1987-03-19 1988-09-27 Microbial Chem Res Found 自己免疫疾患予防治療剤
JPH09503672A (ja) * 1993-10-14 1997-04-15 イミュネックス・コーポレーション Ｆａｓ拮抗剤とその利用
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
NZ311174A (en) * 1995-06-30 1999-04-29 Mochida Pharm Co Ltd Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody
US6399327B1 (en) * 1995-07-16 2002-06-04 Yeda Research And Development Co. Ltd. Modulators of the function of FAS receptors and other proteins
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
AU2650597A (en) 1996-05-02 1997-11-26 Mochida Pharmaceutical Co., Ltd. Novel fas antigen derivatives
CA2264968A1 (en) * 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand
ATE273713T1 (de) * 1996-10-31 2004-09-15 Mochida Pharm Co Ltd Fas-antagonist für die prophylaxe oder therapie von gvhd
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
EP1033910A4 (de) 1997-10-10 2004-11-24 Cytovia Inc Dipeptid-apoptose-inhibitoren und deren verwendung
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease

Also Published As

Publication number Publication date
DE69932434D1 (de) 2006-08-31
EP1082967B1 (de) 2006-07-19
EP1082967A1 (de) 2001-03-14
EP1082967A4 (de) 2001-11-07
US6759041B1 (en) 2004-07-06
WO1999062554A1 (fr) 1999-12-09
CA2333880A1 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
EA200200208A1 (ru) Синергитическая композиция
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK0679393T3 (da) Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol
NZ516513A (en) Nitric oxide donors for inducing neurogenesis
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE469907T1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69227696D1 (de) Zusammensetzungen zur behandlung von hiv-infektionen
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE333287T1 (de) Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten
DE3679781D1 (de) Verwendung von zusammensetzungen fuer die behandlung und die prophylaxe von epithelialer zerstoerung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties